Natixis’s Core Laboratories CLB Stock Holding History

Natixis’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-30,050	Closed	-$520K	–	1007
2024 Q4	$520K	Buy	+30,050	New	+$580K	﹤0.01%	706

Other funds holding CLB

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Natixis's CLB Position: Q1 2025 in Review

Natixis sold out of Core Laboratories (CLB) in Q1 2025, closing a stake of 30,050 shares — an estimated $520K sold.

Natixis first reported a position in CLB in Q4 2024 and held it in 1 quarter. The position peaked at $520K in Q4 2024. 195 funds tracked by Wall St. Rank hold CLB as of Q1 2025.

Natixis reported no remaining Core Laboratories position as of Q1 2025 after selling out during the quarter.
Natixis sold 30,050 Core Laboratories shares in Q1 2025, an estimated $520K.
Natixis first reported a position in Core Laboratories in Q4 2024 and held it in 1 quarter.
Natixis's Core Laboratories position peaked at $520K in Q4 2024.
195 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2025.

Based on Natixis's 13F filing for Q1 2025, filed 14 May 2025.